ChemoCentryx Announces Publication in The New England Journal of Medicine of Results of the Pivotal Phase III ADVOCATE Trial of Avacopan for the Treatment of ANCA-Associated Vasculitis

    NEXT STORY
    Myovant Sciences and Pfizer Announce Publication in the New England Journal of Medicine of Phase 3 LIBERTY Studies of Once-Daily Relugolix Combination Therapy in Women with Uterine Fibroids
    PREV STORY
    Codiak Announces Closing of $66.4 Million Public Offering, Including Full Exercise of Underwriters’ Option
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    John M. Dineen Appointed to Syneos Health Board of Directors, Named Chairman

    MORRISVILLE, N.C., Dec. 10, 2018 (GLOBE NEWSWIRE) -- Syneos Health™ (Nasdaq:SYNH), the only fully ...

    author_avatar
    NASDAQ Market News

    HTG Molecular Diagnostics Reports Fourth Quarter and Full Year 2015 Results

    TUCSON, Ariz., March 24, 2016 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM), a ...

    author_avatar
    NASDAQ Market News

    Genmab Announces Data to be Presented at 2017 ASCO Annual Meeting

    Media Release 8 abstracts on Genmab programs scheduled for presentation at ASCO Two daratumumab ...

    author_avatar
    NASDAQ Market News